## **C1 Inhibitor and Functional Complement**

| Accreditation Status:               | UKAS Schedule of Accreditation   |
|-------------------------------------|--|
| Date Scheme started:                | 2002   |
| Clinical Applicability:             | Diagnosis of Hereditary Angioedema and monitoring of complement activation   |
| Analytes:                           | Performance will be monitored in the antigenic and functional assays for C1 Esterase Inhibitor. Laboratories are required to return data on Complement C3 and C4 to permit the interpretation of the C1 Esterase Inhibitor levels (SER/033)  |
| Units for Reporting:                | g/L in relation to relevant international standards, functional activity (%)   |
| Samples Distributed:                | Liquid format. Normal and pathological human serum   |
|                                     | Additional materials may be produced by the addition of purified C1 Esterase Inhibitor, C3 or C4 to an analyte free serum matrix   |
| Number of Distributions per year:   | 4  |
| Number of Samples per Distribution: | 2  |
| Frequency of Distributions:         | Every three months as outlined in the <b>Distribution Schedule</b>   |
| Schedule of Analysis:               | <b>Data entry</b> is via the web for the submission of results. Data analysis is commenced 28 days after sample dispatch. Late returns are accepted and will contribute to the laboratory's cumulative performance statistics  |
| Data Analysis:                      | All Laboratory Trimmed Mean (ALTM) with truncation at 2SD, SD, and CV%. Reports also show method and manufacturer specific statistics. Individual laboratory performance is expressed in terms of MRBIS, SDBIS, and MRVIS. The Designated Value (DV) for calculation of VI is the All Laboratory Trimmed Mean (ALTM) |
|                                     | Chosen Coefficient of Variation is 10%   |

MI scoring and MRVIS

Performance Scoring: